Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

This study has been completed.

Study NCT00306176 Information provided by Aristotle University Of Thessaloniki

First Received: March 22, 2006 Last Updated: April 3, 2007 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	October 2006
Estimated Primary Completion Date:	No date given

No publications provided by Aristotle University Of Thessaloniki

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Kadoglou NP, Vrabas IS, Sailer N, Kapelouzou A, Fotiadis G, Noussios G, Karayannacos PE, Angelopoulou N. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. Diabetes Metab. 2010 Apr;36(2):144-51. Epub 2010 Feb 9.

Kadoglou NP, Iliadis F, Angelopoulou N, Sailer N, Fotiadis G, Voliotis K, Vitta I, Liapis CD, Alevizos M. Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes. J Diabetes Complications. 2009 May-Jun;23(3):160-6. Epub 2008 Apr 16.

Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2007 Sep;30(9):2242-4. Epub 2007 Jun 22. No abstract available.